MVP-06-01 / Oncovita - LARVOL DELTA

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma (The Manila Times) - "Oncovita...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, MVdeltaC, for the treatment of pleural mesothelioma-a rare and aggressive cancer with high unmet medical need and limited therapeutic options....'This regulatory support strengthens our strategy to advance innovative immunotherapies as we prepare to enter clinical development with MVdeltaC by 2026.'"

New trial • Orphan drug • Pleural Mesothelioma